Tag Archives: congress

ICYMI: The Hill Op-ed on Ending 340B Abuse

health care, medicine

Writing in The Hill today, Ellen Weaver of the Palmetto Promise Institute and Lindsay Boyd of The Beacon Center of Tennessee call upon Congress to reform the 340B program, created by Congress more than two decades ago. The program aimed to help low-income and uninsured patients afford prescription medications. Qualified hospitals – originally, 90 truly charitable hospitals serving large at-risk populations – received large discounts on the medications they purchased. But, there was one loophole Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO on CNBC: IPR System Weakens Medical Innovation

ron-cohen_115x76

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on CNBC’s Fast Money where he discussed our industries concerns’ with the U.S. Patent and Trademark Office’s patent challenge system known as Inter Partes Review (IPR). Dr. Cohen concisely explained this complicated and rapidly evolving issue and made clear why Congress must quickly address abuses to the IPR system within current Patent reform legislation. Regrettably, this system that was designed by Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Here are the Facts about the IPR Kill Rate

US_Patent_And_Trademark_Office

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the rapidly increasing number of biopharma related inter partes reviews (IPR) currently within the United States Patent and Trademark Office (PTO). It is troubling that in a single breath Ronny Gal both dismissed the biopharmaceutical industry’s concerns with the PTO’s IPR process and acknowledged that limited data prevents any firm conclusions about the potential impact of IPR on biotech innovation. If Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Reflecting on July 2015: “The Ag Biotech Debate Was Front and Center”

U.S. Capitol Building - Congress

Agri-Pulse recently published an op-ed titled “The Biotechnology Riddle” by Marshall Matz which outlined how ag biotech was “front and center” in both executive and congressional affairs this past July. He guides readers through the actions taken by legislative officials to promote the benefits of biotechnology and scientific literacy. First on July 2nd the White House Office of Science and Technology Policy and the Office of U.S. Trade Representative issued an Executive Memorandum to “Modernize Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

Seventy Nine House Members Express Concern with H.R. 9

Vote No on HR 9

House leaders made the decision earlier this month to remove patent reform legislation from the schedule for the remaining days before the August recess. While a vote is expected to occur sometime in September, House Majority Leader Kevin McCarthy made the decision to review and address many of the concerns that have been voiced by an array of industries that require the value of dependable and enforceable patents. In the words of Representative McCarthy, “I Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,